The Agentic AI Trap: Why Life Sciences Must Shift from Automation to Oversight

The rapid adoption of agentic AI—systems capable of executing multistep tasks like literature review and data analysis—has created a dangerous gap between innovation and accountability. A 2026 NVIDIA survey confirms that 47% of healthcare and life science organizations are already deploying these agents. Yet, according to McKinsey, only 30% of firms have established the mature governance structures required to manage the risks of AI operating outside human-defined guardrails.

Ome Ogbru, founder and CEO of AINGENS, warns that the industry is misinterpreting the term "agent." While these systems can streamline labor-intensive workflows, they lack the capacity for accountability. In a regulated environment, an AI that selects the wrong source or omits contradictory evidence without a transparent audit trail can compromise medical claims and patient safety. Ogbru advocates for "evidence-bound" AI, where the system is strictly confined to user-defined knowledge bases and forced to flag missing data rather than hallucinating answers. As organizations evaluate new tools, they must move beyond speed-based metrics and prioritize systems that offer full traceability, ensuring that human experts remain the final authority on every stage of scientific output.